Turn this list into pipeline.
Pharmaceutical Companies in Southampton: 51 Active Firms (2026)
Pharmaceutical companies develop, manufacture or distribute regulated medicines for healthcare markets in and around Southampton.
Commercial activity around Southampton tends to split between specialist import and wholesale supply, regulatory and licensing work, and development-led functions that need access to research partners. Buyers are mainly healthcare providers, wholesalers, research organisations and overseas market partners, rather than consumers. The practical buying centre is often a regulatory, commercial or supply-chain team looking for dependable access to licensed products, compliant storage and distribution, or support moving a product through authorisation. Engagements therefore tend to be relationship-led and contract-based, with lower-mid-market operators carrying specialist functions on lean staffing rather than building broad national sales machines.
Read more
Southampton has 51 pharmaceutical companies actively trading, making this a compact local cohort rather than a national cluster in miniature. Commercial maturity is uneven: 6 companies report turnover above £5M, while 17 were incorporated since 2022. The employment footprint looks lean, with 27 staff reported by firms that disclose headcount. That combination points to a market shaped by small importers, wholesalers, licence-holders and development-stage operators, alongside a narrower group with material UK sales. For researchers, the distinction matters because revenue scale, not incorporation age, is the cleaner guide to which firms are likely to buy regulated supply, quality, pharmacovigilance or market-access support.
Human medicines activity falls under the MHRA, with obligations determined by what a business actually does: manufacturing, assembling, importing, wholesaling, running trials or holding authorisations. Manufacturers and importers need a manufacturer’s licence, good manufacturing practice compliance and regular site inspection. Wholesalers supplying anyone other than the patient need a wholesale distribution licence and good distribution practice compliance. Medicines also need marketing authorisation, while post-market safety monitoring sits inside pharmacovigilance systems. Public health-service access adds another gate, because cost-effectiveness review can determine whether an authorised medicine reaches routine procurement. ABPI remains the main trade body for research-based pharmaceutical companies.
Southampton’s pharmaceutical base appears likely to stay specialised rather than broad-based. Lean staffing and the weight of younger operators tend to favour focused importing, distribution, licensing and development support, where compliance capability can matter as much as local sales reach. Scale-up scarcity may also make partnerships more important than standalone expansion, particularly for firms that need manufacturing oversight, trial governance or market-access evidence without carrying every function in-house. Consolidation pressure has been a recurring feature in regulated medicines supply, but local specialists can remain relevant where they hold licences, trading relationships or knowledge of particular therapeutic and international routes.
51
Active firms
2026
6
Reported revenue
above £5M
17
Newer firms
incorporated since 2022
Key facts
About 11% of the trading cohort reports turnover above £5M (6 of 51 firms) — the rest sits below that revenue band.
33% of the cohort was incorporated since 2022 (17 firms), so a sizeable share is in its first few filing cycles.
UK human medicines are regulated by the MHRA, with manufacturing, importing and assembly subject to manufacturer’s licensing, good manufacturing practice and regular site inspections.
Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance.
Pharmaceutical R&D performed by UK businesses was £9.0 billion in 2022, equivalent to 0.36% of UK GDP and 18% of UK business R&D.
UK pharmaceutical exports were £25.6 billion in 2023, with the UK ranked tenth among comparator countries.
In 2022, the UK’s share of patients recruited to a subset of commercial clinical trials was 2.6%, ranking fourth among comparator countries.
Top Southampton Pharmaceutical companies
Synairgen
Develops antiviral therapies for severe respiratory viral infections. Focuses on inhaled interferon beta (SNG001) delivered to the lungs and conducts clinical research and trials evaluating…
Targets hospitals, clinicians and healthcare systems treating patients hospitalised with severe viral respiratory infections, including COVID-19, influenza, RSV and related viruses.
Location
Synairgen
Develops antiviral therapies for severe respiratory viral infections. Focuses on inhaled interferon beta (IFN‑β) drug candidates, including SNG001, and conducts clinical research and clinical trials…
Serves hospitals, healthcare systems and clinicians treating patients hospitalised with severe respiratory viral infections, including COVID-19, influenza and RSV.
Location
CORE ENVIRONMENTAL PLC
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
AMELA INTERNATIONAL LTD
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
M JALLOW LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
Alissa Healthcare Research Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops, licenses, markets and distributes generic and speciality medicines. Supplies pharmaceutical products to healthcare providers and pharmacies and collaborates with partners to bring licensed…
Sells to UK healthcare buyers, particularly the NHS and pharmacies, and serves pharmaceutical customers and collaboration partners in the UK, EU and worldwide. Targets B2B and public sector medicine…
Financial Health
HealthyHealthy · -3% CAGR over 4y
Location
INNOVESUS LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
COMPASS PHARMA LTD
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable · 0% CAGR over 3y
Location
NIPRO DIAGNOSTICS (UK) LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · -67% CAGR over 4y
Location
The Nature Uc Ltd
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed
Location
Workstead Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
KPB HEALTHCARE LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
Qures Healthcare Limited
Trajectory
4y · 2022–NowFinancial Health
Insufficient historyInsufficient history
Location
Instachem Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Muzo Health Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed
Location
MEDIPHARMA LIMITED
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -50% CAGR over 6y
Location
WING LING LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
HealthyHealthy · 0% CAGR over 2y
Location
BIOPHARMA TECHNOLOGY LIMITED
Trajectory
3y · 2023–NowProvides contract development and manufacturing services for pharmaceutical, biotechnology and diagnostic products, specialising in lyophilization. Offers formulation and cycle development,…
Serves B2B customers in the US diagnostics, pharmaceutical and biotechnology sectors, including R&D, manufacturing and product development teams working with lyophilized products or liquid…
Financial Health
Insufficient historyInsufficient history
Location
HARTLEY MEDICAL SERVICES LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides compounding pharmacy services specialising in intrathecal medications used in targeted drug delivery for chronic pain and spasticity. Produces sterile compounded drugs, offers clinical…
Serves pain management physicians, clinical teams and intrathecal pump practices treating patients with chronic pain, spasticity and cancer pain.
Financial Health
StableStable · -9% CAGR over 2y
Location
Unlock all 51 leads
Showing 19 of 51 — +32 more with verified decision-maker contacts, live data, and CRM sync.
How Southampton Pharmaceutical companies work and how to sell to them
What they do
Southampton pharmaceutical firms tend to earn revenue through gross margin on imported, licensed or wholesaled medicines, service fees for regulatory and quality work, and contract payments tied to development or market-entry projects. The sale is usually a regulated product or capability rather than a self-serve purchase: stocked medicines, access to a licence, batch release oversight, pharmacovigilance processes, or a managed route into UK distribution. Pricing therefore tends to sit in framework agreements, supply contracts, retainers and project fees, with volume discounts where physical stock is moving. Smaller operators may carry a narrow licence set or therapeutic focus, so relevance often depends on matching the exact regulated activity rather than the broad pharmaceutical label.
Who they sell to
Most sell to other regulated organisations: healthcare providers, pharmacy groups, wholesalers, contract research partners, development sponsors and overseas distributors. The day-to-day buyer may be a responsible person, quality lead, regulatory affairs manager, procurement head or commercial director, with finance and the managing director pulled in where margin, credit risk or licence exposure matters. Larger healthcare and public-sector routes tend to use tenders, preferred-supplier lists or framework procurement, while private wholesale and licensing deals are more relationship-led. Sales cycles are rarely instant, because onboarding normally involves quality checks, trade references, credit review, licence review and evidence that storage, distribution and safety processes can pass scrutiny.
What they buy
Most Southampton pharmaceutical firms tend to spend on systems and services that reduce compliance load or protect supply continuity. Relevant software categories include quality management, document control, inventory and batch tracking, pharmacovigilance case handling, supplier qualification, finance, CRM and analytics. Services often include regulatory affairs advice, MHRA inspection readiness, GDP or GMP training, responsible-person cover, accounting, tax, legal contracting, insurance, logistics, temperature-controlled storage, and recruitment for quality, regulatory and supply-chain roles. Development-led firms may also buy clinical operations support, medical writing, market-access evidence work and partner search. Pitches tend to land better when they map to a licence condition, audit requirement, release bottleneck or margin leakage, rather than a generic efficiency claim.
Why and how to sell to them
Commercial intent tends to appear when a pharmaceutical operator adds a licence, prepares for inspection, takes on a new overseas supplier, wins a supply agreement, expands warehousing, hires quality or regulatory staff, or moves a development asset towards authorisation. Common pain points are audit fatigue, duplicated quality documentation, fragile supplier assurance, batch-traceability gaps, cold-chain risk, cash tied up in stock, and long payment cycles. Outbound should be specific about the regulated workflow it improves and the buyer role it helps. A message for a quality lead should sound different from one for a commercial director: one is guarding inspection readiness, the other is trying to protect margin and availability.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Southampton
Related directories
Frequently asked questions
How many pharmaceutical companies are there in Southampton?
What counts as a pharmaceutical company in this list?
Which are the largest pharmaceutical companies in Southampton?
What do pharmaceutical companies in Southampton actually do?
How does Southampton pharmaceutical compare internationally?
How is this list built and how fresh is the data?
How big are the typical pharmaceutical companies in Southampton?
Are these mostly new or established pharmaceutical companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 51 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.